Myriad Genetics Inc. is a leading molecular diagnostic and precision medicine company that develops and commercializes genetic and genomic tests designed to assess disease risk, guide treatment decisions, and monitor disease progression across high-value clinical specialties. Operating primarily within the U.S. clinical laboratory testing services sector, the company processes patient specimens billed to commercial insurers, government programs, and patients directly. Myriad has systematically expanded its global footprint, notably in Japan. Its commercialized product suite spans three primary clinical specialties: the Cancer Care Continuum (MyRisk, Prolaris, myChoice CDx, Precise MRD), Prenatal Health (Prequel, Foresight, FirstGene), and Mental Health (GeneSight Psychotropic). Healthcare providers choose Myriad due to its deep clinical validation, proprietary genomic database compiled over three decades, comprehensive billing infrastructure, and integration into leading EMR platforms, which creates high switching costs.